Assembly Biosciences to Present at the Jefferies 2016 Global Healthcare Conference
June 01 2016 - 7:30AM
Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company
advancing a new class of oral therapeutics for the treatment of
hepatitis B virus (HBV) infection and novel oral biological
therapeutics addressing disorders associated with the human
microbiome, announced that President and CEO Derek Small will
present at the Jefferies 2016 Global Healthcare Conference in New
York City. The presentation is scheduled for Tuesday, June
7, 2016 at 10:30 AM EDT. A Question and Answer
session will follow the presentation.
The presentation will be webcast live and is available through
this link and at the Events and Presentations page of the company's
website at assemblybio.com. Archived versions of the webcast will
be available for at least 90 days beginning several hours after the
live presentation.
For information on the conference, contact
healthcareconference@jefferies.com.
About Assembly Biosciences Assembly
Biosciences, Inc. is a public biotechnology company developing
two innovative platform programs: an HBV-cure program advancing a
new class of oral therapeutics for the treatment of hepatitis B
virus (HBV) infection and a microbiome program developing novel
oral biological therapeutics designed to address diseases
associated with the human microbiome. Assembly's HBV-cure program
aims to increase the current low cure rates for chronic HBV. The
company’s highly experienced HBV team has collectively brought more
than 10 anti-infective products to the market. They are pursuing
several drug candidates that inhibit multiple viral targets
throughout the HBV lifecycle for possible use alone or in
combination therapy. The company’s microbiome program consists of a
fully integrated platform that includes a robust strain
identification and selection process, methods for strain isolation
and growth under current Good Manufacturing Practices and a
patent-pending delivery system, GEMICELTM, which allows for
targeted oral delivery of live biologic and conventional therapies
to the lower gastrointestinal tract. The lead program from this
platform, ABI-M101, is in development for the treatment of C.
difficile infections. Assembly is also developing additional
microbiome product candidates. For more information,
visit assemblybio.com.
Contacts
Corporate:Assembly Biosciences,
Inc.David Barrettdbarrett@assemblybio.com
Media:BLL Partners LLCBarbara
Lindheim212-584-2276blindheim@bllbiopartners.com
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Apr 2023 to Apr 2024